

**PREVENTING, DIAGNOSING, AND TREATING CANCER
WORKING WITH INDUSTRY TO PROMOTE PUBLIC HEALTH**

**MARRIOTT BETHESDA NORTH HOTEL AND CONFERENCE CENTER
BETHESDA, MD**

SEPTEMBER 25, 2007

AGENDA

7:00 a.m.–8:00 a.m.	Registration, Networking, and Continental Breakfast
8:00 a.m.–8:30 a.m.	Welcoming Remarks <i>John Niederhuber, M.D., Director, National Cancer Institute</i> <i>Renee Winsky, Executive Director, Maryland Technology Development Corporation</i> <i>Julie Coons, President, Tech Council of Maryland</i>
8:30 a.m.–9:00 a.m.	Keynote Speaker: Partnerships in Basic and Clinical Research <i>Robert Wiltrout, Ph.D., Director, Center for Cancer Research, National Cancer Institute</i>
9:00 a.m.–9:15 a.m.	Overview: The National Institutes of Health Licensing <i>Mojdeh Bahar, J.D., M.A., Technology Licensing Specialist</i> <i>Office of Technology Transfer, The National Institutes of Health</i>
9:15 a.m.–9:30 a.m.	Overview: Research Collaborations with the National Cancer Institute <i>Karen Maurey, Director, Technology Transfer Center, National Cancer Institute</i>
9:30 a.m.–9:45 a.m.	Break: Networking, Exhibits, and Posters
9:45 am – 10:00 am	Special Briefing: Available NCI STTR/SBIR Funding Opportunities
10:00 a.m.–10:30 a.m.	Success Story: HPV Vaccine: An Industrial Partnership to Prevent Cervical Cancer <i>Douglas R. Lowy, M.D., Chief, Basic Research Laboratory and Laboratory of Cellular Oncology, National Cancer Institute</i>
10:30 a.m.–11:30 a.m.	Session I: Cancer Therapeutics <ul style="list-style-type: none"> • TIMP-2, an Angio-Inhibitory Agent of and Inductor of Chemo-Sensitization in Human Lung Cancer Cells <i>William G. Stetter-Stevenson, M.D., Ph.D., Head, Extracellular Matrix Pathology Section, Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute</i> • JS-K and PABA/NO as Anti Tumor Agents <i>Larry K. Keefer, Ph.D., Chief, Laboratory of Comparative Carcinogenesis, Center for Cancer Research, NCI-Frederick</i> • An Engineered Selenocysteine Defines A New Class of Pharmaceuticals <i>Christoph Rader, Ph.D., Senior Scientist and Head, Antibody, Technology Section, Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute</i> • Potent, Easy-to-Use Targeted Toxins as Antitumor Agents <i>Nadya I. Tarasova, Ph.D., Staff Scientist, Molecular Aspects of Drug Design Section, Structural Biophysics Laboratory, Center for Cancer Research, NCI-Frederick</i>

	<ul style="list-style-type: none"> • Peptide Inhibitors of Wip1 as Anticancer Agents <i>Ettore Appella, M.D., Head, Chemical Immunology Section, Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute</i> • SIPA-1 Gene and Inhibitor for the Treatment, Prevention, and Diagnosis of Cancer <i>Kent W. Hunter, Ph.D., Senior Investigator, Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute</i> • Tetrafluorinated Thalidomide Analogs with Potent Anti-Angiogenic and Anticancer Properties <i>William Douglas Figg, Sr., Pharm.D., Senior Scientist, Molecular Pharmacology Section, Medical Oncology Branch and Affiliates, Center for Cancer Research, National Cancer Institute</i> • Phospho-Thr Mimetic Peptide as an Anti-Polo Kinase Therapeutic Agent <i>Kyung S. Lee, Ph.D., Head, Chemistry Section, Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute</i>
11:30 a.m.–11:45 a.m.	Break: Networking, Exhibits, and Posters
11:45 a.m.–12:30 p.m.	<p>Session II: Cancer Immunology</p> <ul style="list-style-type: none"> • T-Cell Expansion and an Inducer of CD40 Stimulation in the Treatment of Cancer <i>Jonathan Weiss, Ph.D., Staff Scientist, National Cancer Institute-Frederick</i> • Effective Cell Transfer Immunotherapy for Patients with Metastatic Cancer <i>Steven A. Rosenberg, M.D., Ph.D. Chief, Tumor Immunology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute</i> • Fully Human Monoclonal Antibodies Against Cancer-Related Proteins and Viruses <i>Dimitar S. Dimitrov, Ph.D., Senior Investigator, Nanobiology Program, Protein Interaction Group, Center for Cancer Research, NCI-Frederick</i> • A Novel Anti-Inflammatory Agent to Prevent Fibrosis During Cancer Therapy <i>Shioko Kimura, Ph.D., Senior Investigator, Endocrinology Section, Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute</i> • IL-15 as a Therapy for Metastatic Cancer and the IL-15 Receptor as a Target for Immunotherapy of Lymphoma and Autoimmune Diseases <i>Thomas A. Waldmann, M.D., Chief, Cytokine Immunology and Immunotherapy Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute</i> • Novel Vaccine Strategies for Cancer and AIDS <i>Jay A. Berzofsky, M.D., Ph.D., Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute</i>
12:30 p.m.–1:30 p.m.	Lunch, Networking, and Poster Sessions
1:30 p.m.–2:30 p.m.	<p>Session III: Cancer Diagnostics/Biomarkers/Imaging</p> <ul style="list-style-type: none"> • Nanoscale Diagnostics for Cancer using Ion Abrasion Scanning Electron Microscopy <i>Sriram Subramanian, Ph.D., Senior Investigator, Biophysics Section, Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute</i> • MicroRNAs and Cytokines in Cancer Diagnosis, Prognosis, and Therapeutic Outcome <i>Curtis C. Harris, M.D., Chief, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute</i>

	<ul style="list-style-type: none"> • An ES Cell–Based Functional Assay to Study BRCA2 Variants <i>Shyam K. Sharan, Ph.D., Investigator, Genetics of Cancer Susceptibility Section, Mouse Cancer Genetics Program, Center for Cancer Research, NCI-Frederick</i> • A Rapid Sensitive Multiparameter Flow Cytometric Assay of Whole Blood for Pharmacodynamic Monitoring of Histone Deacetylase Inhibitors <i>Min-Jung Lee, Staff Scientist, Medical Oncology Branch and Affiliates, Center for Cancer Research, National Cancer Institute</i> • Assay to Predict Resistance to Doxorubicin in Breast Cancer <i>Stefan Ambs, Ph.D., Investigator, Breast and Prostate Cancer Unit, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute</i> • A Molecular Probe for <i>In Vivo</i> Monitoring of HER2 Expression in Breast Cancer <i>Jacek Capala, Ph.D., Investigator, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute</i> • Cripto-1 as a Potential Diagnostic Marker in Cancer <i>Caterina Bianco, M.D., Staff Scientist, Mammary Biology and Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute</i> • Pharmacogenetic Markers for Anticancer Treatment Outcome <i>William Douglas Figg, Sr., Pharm.D., Senior Scientist, Molecular Pharmacology Section, Medical Oncology Branch and Affiliates, Center for Cancer Research, National Cancer Institute</i>
2:30 p.m.–4:00 p.m.	<p>In Exhibit Area: Poster Sessions Networking Reception Sponsored by Montgomery County Office of Economic Development</p>
4:00 p.m.	<p>Adjourn</p>